Members of the Cancer Cell Biology (CB) Program study the cell cycle, signal transduction, apoptosis, cell development, cell differentiation, stem cell biology, immune and inflammatory responses and metastasis. They are engaged in determining the drivers of these processes in cancer and translating this knowledge into potential biomarkers and therapeutic approaches and targets for cancer patients. Novel technologies and approaches to address these areas developed by the program include facile animal models to study cancer stem cells, signaling and apoptosis, mass spectrometric analysis of unique tumor epigenetic modifications, functional genomic drug screens and cancer vaccine development. CB has four interconnected focus groups: 1) Signal Transduction and Apoptosis;2) Cell Cycle Regulation and Proliferation;3) Development, Stem Cells and Cancer;4) Inflammation, Immunity and Metastasis. In the prior funding period, CB made major contributions to the field, including: 1) Identified a novel oncogene using a frog model system (Repo-Man);2) Determined the mechanism of action of Silibinin (IP6) a chemopreventive compound;3) Developed novel therapeutics from knowledge of signal transduction, apoptosis and cell cycle pathways (e.g. Mer TK and p27 targets);4) Investigated IL-lb-mediated inflammation's role in melanoma metastasis;5) Discovered novel epigenetic markers (histone H3 K56);6) demonstrated the p53 gain of function mutations confer a worse prognosis than p53 deletion;and, 7) Tested the cancer stem cell hypothesis using novel animal models (BCR and MYC in skin). CB has 66 full members in 20 Departments and 6 schools on the University of Colorado Denver, University of Colorado Boulder, National Jewish Health, and the Colorado State University campuses holding $2.7 million direct costs in NCI grants and $23.7 million direct costs in other cancer-relevant support in the last budget year. Between 2005 and 2010, per capita cancer research funding increased by 40% from $286K to over $400K. CB produced 869 cancer-related publications from 2005 through 2010. Of these, 230 (26.5%) were inter-programmatic publications;66 (7.6%) were intra-programmatic publications;and 36 (4%) were both inter- and intra-programmatic. Thus, 332 (38%) of the total cancer-related publications by memtjers of this program were collaborative. Importantly, more than 2/3 of CB members published collaborative peer reviewed papers in the last funding period with other UCCC members.
The Cancer Cell Biology Program organizes UCCC researchers who study how cellular processes function in the development and progression of cancer. Understanding how cancer changes the way cells function can help biomedical researchers discover new ways to prevent and treat it.
|Finlay-Schultz, J; Cittelly, D M; Hendricks, P et al. (2015) Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene 34:3676-87|
|Alvarez-Calderon, Francesca; Gregory, Mark A; Pham-Danis, Catherine et al. (2015) Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res 21:1360-72|
|Kumar, Sushil; Raina, Komal; Agarwal, Chapla et al. (2014) Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotarget 5:4972-89|
|Roth, Lauren W; Allshouse, Amanda A; Bradshaw-Pierce, Erica L et al. (2014) Luteal phase dynamics of follicle-stimulating and luteinizing hormones in obese and normal weight women. Clin Endocrinol (Oxf) 81:418-25|
|Roth, Lauren W; Bradshaw-Pierce, Erica L; Allshouse, Amanda A et al. (2014) Evidence of GnRH antagonist escape in obese women. J Clin Endocrinol Metab 99:E871-5|
|Colussi, Timothy M; Costantino, David A; Hammond, John A et al. (2014) The structural basis of transfer RNA mimicry and conformational plasticity by a viral RNA. Nature 511:366-9|
|Griesinger, Andrea M; Donson, Andrew M; Foreman, Nicholas K (2014) Immunotherapeutic implications of the immunophenotype of pediatric brain tumors. Oncoimmunology 3:e27256|
|Marek, Lindsay A; Hinz, Trista K; von Mässenhausen, Anne et al. (2014) Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res 12:1460-9|
|Holliday, Michael J; Zhang, Fengli; Isern, Nancy G et al. (2014) 1H, 13C, and 15N backbone and side chain resonance assignments of thermophilic Geobacillus kaustophilus cyclophilin-A. Biomol NMR Assign 8:23-7|
|Milgroom, Andrew; Intrator, Miranda; Madhavan, Krishna et al. (2014) Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids Surf B Biointerfaces 116:652-7|
Showing the most recent 10 out of 678 publications